Functional cure, defined by hepatitis B surface antigen (HBsAg) loss, is rare during nucleos(t)ide analogue (NA) therapy and guidelines on finite NA therapy have not been well established. We aim to analyze off-therapy outcomes following NA cessation in a large, international, multi-center, multi-ethnic cohort of chronic hepatitis B (CHB) patients.